Assembly Biosciences presented new clinical and preclinical data for its long-acting herpes simplex virus candidate ABI-5366 at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clinical data from a Phase 1a evaluation showed ABI-5366 was well-tolerated up to 350 mg orally, with no Grade 3 or 4 treatment-related laboratory abnormalities or serious adverse events.
The observed half-life of approximately 20 days for ABI-5366 supports the potential for once-weekly or once-monthly oral administration, a significant improvement in convenience. Preclinical data further demonstrated broad activity against both HSV type 1 and HSV type 2 clinical isolates, along with distribution to tissues relevant to HSV infection.
An additional poster highlighted insights into genital herpes prevalence and treatment patterns in the U.S., estimating 1.35 million individuals experience recurrent genital herpes. The analysis indicated that 97% of recurrent cases receive pharmacologic treatment, underscoring the substantial burden and the need for improved therapeutic options that ABI-5366 aims to address.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.